OR WAIT null SECS
January 05, 2018
The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.
January 02, 2018
Bio/pharma professionals manage expectations amid industry uncertainty.
Will business decisions and drug pricing policies help or hinder science and drug approval advances in 2018?
December 28, 2017
The companies have entered an agreement involving assay development and the manufacturing of kits supporting biomarker research programs.
December 19, 2017
The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.
December 12, 2017
The partnership aims to develop and commercialize a skin-care drug candidate being developed to treat actinic keratosis, which, left untreated, can progress to cancer.
December 08, 2017
Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.
December 04, 2017
The acquisition deepens Astellas’ involvement in the development of a pipeline of therapeutics focused on mitochondrial function.
December 01, 2017
Lonza has entered into strategic license agreements for exclusive rights to a gene-therapy platform for developing treatments for hearing and balance disorders.
November 29, 2017
Biocad and Sothema Labs have partnered to release cancer-treating biosimilars into the North African market.